Suppr超能文献

熊去氧胆酸(UDCA)合成的最新进展:综述

Latest development in the synthesis of ursodeoxycholic acid (UDCA): a critical review.

作者信息

Tonin Fabio, Arends Isabel W C E

机构信息

Department of Biotechnology, Delft University of Technology, Van der Maasweg 9, 2629 HZ Delft, The Netherlands.

出版信息

Beilstein J Org Chem. 2018 Feb 20;14:470-483. doi: 10.3762/bjoc.14.33. eCollection 2018.

Abstract

Ursodeoxycholic acid (UDCA) is a pharmaceutical ingredient widely used in clinics. As bile acid it solubilizes cholesterol gallstones and improves the liver function in case of cholestatic diseases. UDCA can be obtained from cholic acid (CA), which is the most abundant and least expensive bile acid available. The now available chemical routes for the obtainment of UDCA yield about 30% of final product. For these syntheses several protection and deprotection steps requiring toxic and dangerous reagents have to be performed, leading to the production of a series of waste products. In many cases the cholic acid itself first needs to be prepared from its taurinated and glycilated derivatives in the bile, thus adding to the complexity and multitude of steps involved of the synthetic process. For these reasons, several studies have been performed towards the development of microbial transformations or chemoenzymatic procedures for the synthesis of UDCA starting from CA or chenodeoxycholic acid (CDCA). This promising approach led several research groups to focus their attention on the development of biotransformations with non-pathogenic, easy-to-manage microorganisms, and their enzymes. In particular, the enzymatic reactions involved are selective hydrolysis, epimerization of the hydroxy functions (by oxidation and subsequent reduction) and the specific hydroxylation and dehydroxylation of suitable positions in the steroid rings. In this minireview, we critically analyze the state of the art of the production of UDCA by several chemical, chemoenzymatic and enzymatic routes reported, highlighting the bottlenecks of each production step. Particular attention is placed on the precursors availability as well as the substrate loading in the process. Potential new routes and recent developments are discussed, in particular on the employment of flow-reactors. The latter technology allows to develop processes with shorter reaction times and lower costs for the chemical and enzymatic reactions involved.

摘要

熊去氧胆酸(UDCA)是一种在临床上广泛使用的药物成分。作为胆汁酸,它可溶解胆固醇胆结石,并在胆汁淤积性疾病中改善肝功能。UDCA可从胆酸(CA)获得,胆酸是最丰富且最便宜的可用胆汁酸。目前用于获取UDCA的化学路线最终产品收率约为30%。对于这些合成方法,必须进行几个需要有毒和危险试剂的保护和脱保护步骤,从而产生一系列废物。在许多情况下,胆酸本身首先需要从胆汁中的牛磺胆酸和甘氨胆酸衍生物制备,从而增加了合成过程的复杂性和步骤数量。由于这些原因,已经开展了多项研究,旨在开发从CA或鹅去氧胆酸(CDCA)合成UDCA的微生物转化或化学酶法。这种有前景的方法促使几个研究小组将注意力集中在利用非致病性、易于管理的微生物及其酶进行生物转化的开发上。特别是,所涉及的酶促反应包括选择性水解、羟基官能团的差向异构化(通过氧化和随后的还原)以及甾体环中合适位置的特定羟基化和脱羟基化。在本综述中,我们批判性地分析了通过几种报道的化学、化学酶法和酶法生产UDCA的技术现状,突出了每个生产步骤的瓶颈。特别关注前体的可用性以及过程中的底物负载量。讨论了潜在的新路线和最新进展,特别是关于流动反应器的应用。后一种技术能够开发出反应时间更短、所涉及的化学和酶促反应成本更低的工艺。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a916/5827811/019dd1c2637b/Beilstein_J_Org_Chem-14-470-g002.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验